Summary
Regeneron Pharmaceuticals, Inc. has entered into a significant amendment to its collaboration agreement with Aventis Pharmaceuticals, Inc. (now Sanofi-aventis), effective January 7, 2005. The primary impact of this amendment is the exclusion of the VEGF Trap for eye diseases delivered via local systems from the scope of the collaboration. Regeneron will now hold exclusive rights to develop and commercialize the VEGF Trap for these specific eye disease indications. In conjunction with this change, Regeneron received a $25 million payment from Sanofi-aventis, with a portion of this amount subject to repayment upon commercialization of the VEGF Trap. Furthermore, Sanofi-aventis reaffirmed its commitment to developing the VEGF Trap for oncology indications in collaboration with Regeneron. This strategic shift allows Regeneron to focus on specific eye disease applications while maintaining its oncology partnership.
Key Highlights
- 1Regeneron and Aventis (Sanofi-aventis) amended their collaboration agreement on January 7, 2005.
- 2The VEGF Trap for eye diseases via local delivery systems has been excluded from the collaboration scope.
- 3Regeneron regains exclusive rights to develop and commercialize the VEGF Trap for local eye disease delivery.
- 4Sanofi-aventis made a $25 million payment to Regeneron, with 50% potentially repayable upon commercialization.
- 5Sanofi-aventis reaffirmed its commitment to the VEGF Trap in oncology development with Regeneron.
- 6Regeneron and Sanofi-aventis do not currently plan to pursue systemic delivery of the VEGF Trap for eye disease.